TY - JOUR T1 - Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent JF - Anticancer Research JO - Anticancer Res SP - 3741 LP - 3749 VL - 37 IS - 7 AU - YOSHITAKA HONMA AU - NOBUKAZU HOKAMURA AU - KENGO NAGASHIMA AU - KAZUKI SUDO AU - HIROKAZU SHOJI AU - SATORU IWASA AU - ATSUO TAKASHIMA AU - KEN KATO AU - TETSUYA HAMAGUCHI AU - NARIKAZU BOKU AU - REI UMEZAWA AU - YOSHINORI ITO AU - JUN ITAMI AU - KAZUO KOYANAGI AU - HIROYASU IGAKI AU - YUJI TACHIMORI Y1 - 2017/07/01 UR - http://ar.iiarjournals.org/content/37/7/3741.abstract N2 - Background: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. Patients and Methods: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. Results: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. Conclusion: Over 30% of patients with resectable M1LYM treated with curative intent achieved long-term survival. ER -